How to cite item

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus

   
@article{ATM18681,
	author = {Constantine E. Kosmas and Andreas Sourlas and Kyriaki V. Bouza and Eddy DeJesus and Delia Silverio and Peter D. Montan and Eliscer Guzman},
	title = {Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus},
	journal = {Annals of Translational Medicine},
	volume = {6},
	number = {7},
	year = {2018},
	keywords = {},
	abstract = {Cardiovascular disease (CVD) is the leading global cause of death and accounts for approximately 30% of the total annual deaths worldwide (1). In the United States, CVD is very common and affects over one third of the population (2). It is well established that low-density lipoprotein cholesterol (LDL-C) is involved in the pathogenesis of atherosclerosis, and treatment with LDLC- lowering medications has elicited a marked reduction in cardiovascular risk in both primary (3) and secondary (4) prevention.},
	issn = {2305-5847},	url = {https://atm.amegroups.org/article/view/18681}
}